Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Under Fasted Conditions

This study has been completed.

Sponsor:

Information provided by:

Roxane Laboratories

ClinicalTrials.gov Identifier:

NCT01010139

First received: November 6, 2009

Last updated: NA

Last verified: November 2009

History: No changes posted

Purpose

The objective of this study designed to characterize the pharmacokinetics and comparative bioavailability of Roxane Laboratories' codeine sulfate tablets after oral administration of 60 mg doses as 1 x 60 mg, 2 x 30 mg and 4 x 15 mg under fasted conditions.

Condition	Intervention
Pain	Drug: Codeine Sulfate


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Single Dose, 3-Period, 3-Treatment, 6-Sequence Crossover Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Tablet Formulations Under Fasting Conditions

Resource links provided by NLM:

Drug Information available for: Codeine Sulfate ion

U.S. FDA Resources

Further study details as provided by Roxane Laboratories:

Primary Outcome Measures:

bioequivalence determined by statistical comparison Cmax [ Time Frame: 21 Days ]


Enrollment:	18
Study Start Date:	August 2006
Study Completion Date:	September 2006
Primary Completion Date:	September 2006 (Final data collection date for primary outcome measure)

Intervention Details:

15 mg, 30 mg and 60 mg Tablet

Eligibility


Ages Eligible for Study:	18 Years to 45 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.

Exclusion Criteria:

Positive test for HIV, Hepatitis B, or Hepatitis C.
Treatment with known enzyme altering drugs.
History of allergic or adverse response to codeine sulfate or any comparable or similar product.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01010139

Locations


United States, Texas
CEDRA Clinical Research
San Antonio, Texas, United States, 78217

Sponsors and Collaborators

Roxane Laboratories

Investigators


Principal Investigator:	James P Doherty, DO	CEDRA Clinical Research

More Information


Responsible Party:	Elizabeth Ernst, Director, Drug Regulatory Affairs and Medical Affairs, Roxane Laboratories, Inc.
ClinicalTrials.gov Identifier:	NCT01010139 History of Changes
Other Study ID Numbers:	CODE-T60-PLFS-1
Study First Received:	November 6, 2009
Last Updated:	November 6, 2009

Additional relevant MeSH terms:


Codeine Analgesics, Opioid Narcotics Central Nervous System Depressants Physiological Effects of Drugs	Analgesics Sensory System Agents Peripheral Nervous System Agents Antitussive Agents Respiratory System Agents

ClinicalTrials.gov processed this record on July 19, 2017

To Top